宫颈癌;流行病学;发病率;死亡率;防治," /> 宫颈癌;流行病学;发病率;死亡率;防治,"/> Cervical cancerEpidemiologyIncidence rateMortalityPrevention and cure,"/> <span style="font-family:'Times New Roman','serif';">Prevalence and prevention strategies of cervical cancer in the world and China</span>

Chinese Clinical Oncology ›› 2023, Vol. 28 ›› Issue (01): 90-93.

Previous Articles    

Prevalence and prevention strategies of cervical cancer in the world and China

  

  1. Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081
  • Received:2022-06-24 Revised:2022-10-19 Online:2023-01-31 Published:2023-03-08

Abstract:  The International Agency for Research on Cancer (IARC) estimates 36 cancer incidence rate and mortality rates in 185 countries/regions through GLOBOCAN 2020 database. Globocan2020 database shows that cervical cancer is the fourth largest tumor in women in the world, whether it is morbidity or mortality. The harm of cervical cancer to women's health and its prevention and treatment are important public health issues facing the world. This paper will summarize and compare the incidence and death prevalence of cervical cancer in the world and China from the aspects of population characteristics, regional distribution and time change trend, and combined with the reported human papillomavirus and other risk factors, primary prevention and secondary prevention strategies of cervical cancer, in order to provide scientific clues for the prevention and treatment strategies of cervical cancer in the future.

Key words: font-size:10.5pt, Cervical cancer">Cervical cancerfont-size:10.5pt, ">;font-size:10.5pt, Epidemiology">Epidemiologyfont-size:10.5pt, ">;font-size:10.5pt, Incidence rate">Incidence ratefont-size:10.5pt, ">;font-size:10.5pt, Mortality">Mortalityfont-size:10.5pt, ">;font-size:10.5pt, Prevention and cure')">">Prevention and cure

CLC Number: 

  •  
[1] LIANG Zongying, ZHAO Baoshan, ZHENG Jingxiong, HOU Jishen, SUN Guangrui..  Correlation of acetyltransferase KAT2A and survivin protein acetylation in esophageal cancer [J]. Chinese Clinical Oncology, 2023, 28(01): 16-22.
[2] QIU Sichong, XU Luyu, LI Liuning.  Construction and validation of prognostic nomogram for malignant meningioma based on SEER database [J]. Chinese Clinical Oncology, 2023, 28(01): 30-37.
[3] ZHAN Tianpeng, HE Wei, ZHANG Meng, TAO Yan, LU Jianzhong, FU Shengjun, LI Lanlan, ZHANG Jing, LIU Shanhui.  Clinical prognostic value and molecular mechanism of UBE2C gene in kidney renal clear cell carcinoma [J]. Chinese Clinical Oncology, 2023, 28(01): 49-57.
[4] XUE Luxin, ZHANG Zhifan, LIU Fangcen, WANG Xiaolu, WANG Qin, LIU Baorui, LI Rutian..  Current status and prospect of immune checkpoint inhibitors in treatment of advanced soft tissue sarcoma [J]. Chinese Clinical Oncology, 2023, 28(01): 77-83.
[5] LIU Delong, JIANG Suibin, GUO Dongming..

Experimental study of MALAT1 targeting miR-205 and invasion of osteosarcoma  [J]. Chinese Clinical Oncology, 2018, 23(5): 385-390.

Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!